Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cohort 1 and 2
Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
Age ≥18 years
Willing and able to provide signed informed consent
Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel
Cohort 3
Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known.
Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD).
Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy.
You may not be if
Cohort 1 and 2
\- None
Cohort 3
Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM
Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry.
Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified
Clareo Health | Connect® MM- The Multiple Myeloma Disease Registry
